Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

Simple Summary KRAS is the most frequently mutated oncogene in non-small cell lung
cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation …

KRAS mutations are one of the most common genetic abnormalities in cancer, especially
lung, colon, and pancreatic cancers. Strategies targeting the oncogenic KRAS pathway …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

KRAS mutations are one of the most frequent activating alterations in carcinoma. Recent
efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Background While the correlation between PD-L1 expression and KRAS mutation has been
previously reported in other solid tumors such as non-small cell lung cancer (NSCLC) …

KRAS is the most commonly mutated oncogene. Targeted therapies have been developed
against mediators of key downstream signaling pathways, predominantly components of the …

Background Chronic lymphocytic leukemia (CLL) is the most frequent, and still incurable,
form of leukemia in the Western World. It is widely accepted that cancer results from an …

Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …